Purpose: This study aimed to determine whether procalcitonin-to-albumin ratio (PAR) and C-reactive protein-to-albumin ratio (CAR) can be alternatives to the Multinational Association for Supportive Care in Cancer (MASCC) risk index score in predicting bacteriemia, septicemia, death during FN, and 28-day mortality, in patients with febrile neutropenia (FN).
Methods: This is a prospective observational study that included 185 participants with FN. Clinical and laboratory findings like PAR and CAR were analyzed, and their ability to predict FN complications was investigated.
Results: From the included population, the 91 subjects (49.46%) had low-risk FN with MASCC risk index ≥ 21. Sixteen participants (8.70%) had bacteremia, and eight developed septicemia (4.89%). Before resolving FN, 15 people died, and in total 33 died within 28 days of diagnosis. The ROC curve analysis indicates that the CAR (p = 0.0008921) better predicts mortality during FN, and the PAR (p = 0.0003535) better predicts bacteremia. Incorporating CAR values into the MASCC risk index predicts mortality by as much as 33.33% more precisely than the MASCC risk index alone. The CAR values > 2.74 were an independent predictor of 28-day mortality (OR = 3.70; 95% CI = 1.08-13.02; p = 0.0376).
Conclusion: The study results suggest that PAR and CAR can be leveraged as valuable prognostic tools in predicting bacteremia, septicemia, mortality during FN, and 28-day mortality in patients with FN.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00520-025-09329-5 | DOI Listing |
Curr Opin Oncol
February 2025
Department of Dental Oncology, Northern Ontario School of Medicine University/Health Sciences North, Sudbury, Ontario, Canada.
Purpose Of Review: Osteoradionecrosis may often be prevented in context of interprofessional healthcare that includes dental specialists prior to and following completion of the patient's head and neck radiation therapy. Important factors, however, compromise delivery of guideline-concordant management of osteoradionecrosis (ORN), including patient access to this interprofessional care. This review is directed to these and related issues, in order to foster enhanced approaches for ORN management.
View Article and Find Full Text PDFSupport Care Cancer
March 2025
Faculty of Medicine, Department of Pharmacology Clinical Pharmacology and Toxicology, University of Belgrade, Belgrade, Serbia.
Purpose: This study aimed to determine whether procalcitonin-to-albumin ratio (PAR) and C-reactive protein-to-albumin ratio (CAR) can be alternatives to the Multinational Association for Supportive Care in Cancer (MASCC) risk index score in predicting bacteriemia, septicemia, death during FN, and 28-day mortality, in patients with febrile neutropenia (FN).
Methods: This is a prospective observational study that included 185 participants with FN. Clinical and laboratory findings like PAR and CAR were analyzed, and their ability to predict FN complications was investigated.
Support Care Cancer
March 2025
Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
Purpose: Sex influences chemotherapy-induced nausea and vomiting (CINV). However, in clinical practice, males and females receive the same antiemetic prophylaxis. We compared CINV between sexes in patients with different emetic risk schemes and evaluated the predisposing factors and main adverse effects caused by antiemetics.
View Article and Find Full Text PDFSupport Care Cancer
March 2025
Network Italiano Cure Di Supporto in Oncologia (NICSO), Universita' Degli Studi Di Brescia, Brescia, Italy.
Purpose: To standardize and improve the safety and efficacy of opioid conversion in people with cancer.
Methods: The Multinational Association of Supportive Care in Cancer (MASCC), American Society of Clinical Oncology (ASCO), American Academy of Hospice and Palliative Medicine (AAHPM), Hospice and Palliative Nurses Association (HPNA), and Network Italiano Cure di Supporto in Oncologia (NICSO) convened an Expert Panel to develop recommendations based on a systematic review of the literature and a formal consensus process. The systematic review focused on randomized and non-randomized studies published from database inception to June 2022.
Support Care Cancer
February 2025
Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, USA.
Purpose: Prevention of chemotherapy-induced nausea and vomiting (CINV) remains an essential supportive care need for patients receiving cancer treatment. Due to inadequate access to antiemetics in many countries, guideline-recommended CINV prophylaxis is not always possible. Our goal was to formulate antiemetic recommendations for resource-limited settings and define alternative antiemetic regimens for the CINV prophylaxis after highly (HEC) and moderately emetic chemotherapy (MEC), when NK-receptor antagonists are not accessible.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!